Glycemic control is associated with lower odds of mortality and successful extubation in severe COVID-19.

Context: Corticosteroids, specifically dexamethasone, have become the mainstay of treatment for moderate to severe COVID-19. Although the RECOVERY trial did not report adverse effects of corticosteroids, the METCOVID (Methylprednisolone as Adjunctive Therapy for Patients Hospitalized with COVID-19) study reported a higher blood glucose level in patients receiving methylprednisolone.

Objectives: This study aims to analyze the association between corticosteroids and COVID-19-related outcomes in patients admitted to the medical ICU (MICU) for COVID-19 pneumonia.